Trial Profile
Compassionate Single Subject Use of FG-3019 in Locally Advanced, Unresectable Pancreatic Cancer (Emergency Use of a Test Article)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2016
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 06 Oct 2016 Status changed from recruiting to withdrawn prior to enrolment as the patient passed before treatment could be started.
- 03 Aug 2016 New trial record